Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Mar 2023
According to market research firm Euromonitor, the global children's cough, cold and allergy products market in 2022 is worth $2.5 billion.
Read Full NewsRoshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.
1.
Have the Harms of Lung Cancer Screening Been Exaggerated?
2.
Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic
3.
Survivors of high-risk neuroblastoma face substantial late effects of modern therapies
4.
Using MRD Status to Deescalate Multiple Myeloma Therapy
5.
Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness
1.
Unlocking the Mysteries of Synovial Sarcoma: A New Hope for Treatment
2.
Mast Cell-Tumor Cell Interactions in OSCC: Genetic and microRNA Insights
3.
Emerging Therapies Through Personalized Tumor Ecosystem Remodeling
4.
Tumor Cell Dormancy Sustained by Extracellular Matrix Mechanical Signaling
5.
Bridging the Global Divide: Enhancing Psychosocial Care for Cancer Survivors Across Income Settings
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
2.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge